Ignite Creation Date:
2024-05-06 @ 10:11 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03182244
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-01
First Post:
2017-06-08
Brief Title:
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia AML With FLT3 Mutation
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Organization Data
Organization:
Astellas Pharma Inc
Class:
INDUSTRY
Study ID:
2215-CL-0303
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Astellas Pharma Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None